Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: PJT PA: ICR - Lev. AI to Transform Can. Res. AI to Accelerate Cancer Research

University of Ottawa

$100,000.00

Developing an AI-enhanced ADC design platform for industrial scalability

EF 2025-26

Résumé
Cancer treatment has advanced significantly with the development of antibody-drug conjugates (ADCs), which deliver chemotherapy directly to cancer cells while minimizing harm to healthy tissue. However, ADC development remains slow, expensive, and highly unpredictable, relying on trial-and-error strategies that lead to high failure rates. This proposal introduces an artificial intelligence (AI)-powered ADC Design Platform to streamline ADC development, improve success rates, and accelerate commercialization. This platform uses AI to analyze a highly curated and uniquely organized database of ADC structures, tumor cell killing potencies, and tumor cell-specific environments relevant to how ADCs work. This enables the platform to predict the most effective combination of antibody, linker, and payload for specific tumor types, eliminating inefficient designs and guiding the precise development of ADCs for specific types of cancers. A core aspect of this project is its direct integration with industry, ensuring that the platform moves beyond academic research into a commercially viable, industry-ready system. This project is positioned with real-world ADC development pipelines, important for its adoption and revenue generation. These revenues will, in turn, support the future competitive edge of the platform and simultaneously facilitate the long-term aim of generating novel ADCs. By addressing a critical gap in ADC development, this initiative seeks to position Canada at the forefront of AI-driven biopharmaceutical innovation and set a new global standard in ADC design and commercialization.
Programme
PJT PA: ICR - Lev. AI to Transform Can. Res. AI to Accelerate Cancer Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
569114
Name
Leyton Jeffrey V
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Commercialization
Projecttitle
Developing an AI-enhanced ADC design platform for industrial scalability
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
PJT PA: ICR - Lev. AI to Transform Can. Res. AI to Accelerate Cancer Research
Keyworddelim
Antibody-Drug Conjugates; Artificial Intelligence; Deep Learning; Machine Learning
Abstract
Cancer treatment has advanced significantly with the development of antibody-drug conjugates (ADCs), which deliver chemotherapy directly to cancer cells while minimizing harm to healthy tissue. However, ADC development remains slow, expensive, and highly unpredictable, relying on trial-and-error strategies that lead to high failure rates. This proposal introduces an artificial intelligence (AI)-powered ADC Design Platform to streamline ADC development, improve success rates, and accelerate commercialization. This platform uses AI to analyze a highly curated and uniquely organized database of ADC structures, tumor cell killing potencies, and tumor cell-specific environments relevant to how ADCs work. This enables the platform to predict the most effective combination of antibody, linker, and payload for specific tumor types, eliminating inefficient designs and guiding the precise development of ADCs for specific types of cancers. A core aspect of this project is its direct integration with industry, ensuring that the platform moves beyond academic research into a commercially viable, industry-ready system. This project is positioned with real-world ADC development pipelines, important for its adoption and revenue generation. These revenues will, in turn, support the future competitive edge of the platform and simultaneously facilitate the long-term aim of generating novel ADCs. By addressing a critical gap in ADC development, this initiative seeks to position Canada at the forefront of AI-driven biopharmaceutical innovation and set a new global standard in ADC design and commercialization.
Competitiondate
202603
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leyton, Jeffrey V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~